Ying Huang

    Ying Huang Ph.D.
    Bank of America Merrill Lynch

    Kate Falberg

    Kathryn “Kate” Falberg
    Director

    Kathryn “Kate” Falberg is Chair of the Audit Committee for the Aimmune Board of Directors and serves as a Board Member and Audit Committee Chair for several life sciences companies. Ms. Falberg currently serves as a Director and Chair of the Audit committee for publicly traded biotechnology companies Medivation, Inc., and Halozyme Therapeutics, where she is also Chairman of the Board, and privately held aTyr Pharma. She previously served on the boards of Ariosa Diagnostics, QLT, VISX, Fresh Del Monte and Human Genome Sciences.

    In over four years as Chief Financial Officer of Jazz Pharmaceuticals, Ms. Falberg led finance, strategy and corporate development and contributed to the company’s rapid growth. Earlier in her career she held several senior financial roles at Amgen, including SVP, Strategy, and CFO. Ms. Falberg received an MBA and BA in Economics from the University of California, Los Angeles, and is a CPA.

    Financial Expert

    Stacey Seltzer

    Stacey D. Seltzer
    Director

    Stacey Seltzer is a partner at Aisling Capital. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company. Ms. Seltzer serves as a director of Miramar Labs. Previously, she served as a Board observer for Agile Therapeutics, Durata Therapeutics and ZELTIQ Aesthetics.

    She also acted as the Aisling representative for its investment in Precision Dermatology and was closely involved in Aisling’s investments in Cytos, Dermira and PowerVision. Ms. Seltzer received her MBA from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her MS and BS from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.

    Mark McDade

    Mark McDade
    Chairman

    Mark McDade is Chairman of the Aimmune Board of Directors and Executive Vice President and Chief Operating Officer of UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research. At UCB, Mr. McDade leads worldwide geographic operations, established brands, technical operations and business development. Previously, Mr. McDade served as CEO and as a Director of PDL Biopharma. He was also CEO of Signature Bioscience; Founder, Chief Operating Officer, President and a Director of Corixa Corporation; and Chief Operating Officer of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange.

    Earlier in his career, Mr. McDade held several positions at Sandoz Ltd., including business development, product management and general management. He serves on the Boards of Directors of Five Prime Therapeutics and Dermira. Mr. McDade received an MBA from the Harvard Business School and a BA in History from Dartmouth College.

    Mark Iwicki

    Mark Iwicki
    Director

    Mark Iwicki is Executive Chairman of the Board of Directors of Kala Pharmaceuticals and sits on the Boards of Nimbus Therapeutics and Taris Biomedical. He was President and CEO of Civitas Therapeutics until late 2014, when it was acquired by Acorda Therapeutics. Prior to joining Civitas, Mr. Iwicki was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He was also President and CEO of Sunovion Pharmaceuticals after leading its launch from the acquisition of Sepracor, where he had been Chief Commercial Officer.

    Previously, Mr. Iwicki was Senior Vice President at Novartis Pharmaceuticals and headed the cardiovascular business unit and additional therapeutic areas. He began his career in sales and marketing at Merck, Astra Merck and AstraZeneca. Mr. Iwicki received an MBA from Loyola University Maryland and a BS in Business Administration and Management from Ball State University.

    Patrick Enright

    Patrick Enright
    Director

    Patrick Enright is a founder and Managing Director of Longitude Capital. Previously, Mr. Enright was a Managing Director of Pequot Ventures. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche) and Sandoz (now Novartis). He currently serves on the boards of CardioDx, Corcept Therapeutics (NASDAQ: CORT), InfaCare Pharmaceuticals, Jazz Pharmaceuticals (NASDAQ: JAZZ) and Xanodyne Pharmaceuticals.

    He has previously served on the boards of Codexis (NASDAQ: CDXS), Horizon Therapeutics (acquired), MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals (acquired), Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.

    Stephen Dilly

      Stephen G. Dilly MBBS, PhD
      Chief Executive Officer

      Stephen G. Dilly, MBBS, PhD, is Aimmune’s Chief Executive Officer. He was formerly the CEO at PhotoThera, Inc., and APT Pharmaceuticals. Dr. Dilly was previously Senior Vice President, Head of Development, and Chief Medical Officer at Chiron BioPharmaceuticals. Before that, he held a number of senior executive clinical, development and commercial support positions at companies including SmithKline Beecham and Genentech.

      Dr. Dilly played important roles in the development and approval of numerous drugs, including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo Activase®, Raptiva®, Xolair®, Avastin®, Lucentis®, Cubicin® and Tarceva®. He is on the Board of Sangamo Biosciences. Dr. Dilly received a PhD in Cardiac Physiology from the University of London and holds an MBBS, graduating as a physician from the University of London.

      Dr. Dilly played important roles in the development and approval of numerous drugs, including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo Activase®, Raptiva®, Xolair®, Avastin®, Lucentis®, Cubicin® and Tarceva®. He is on the Board of Sangamo Biosciences. Dr. Dilly received a PhD in Cardiac Physiology from the University of London and holds an MBBS, graduating as a physician from the University of London.

      Warren DeSouza

        Warren DeSouza
        Chief Financial Officer

        Warren DeSouza is Aimmune’s Chief Financial Officer. Mr. DeSouza has 25 years of combined experience in biotechnology finance and audit-assurance consulting. He was most recently Vice President, Finance, at Onyx Pharmaceuticals. In nine years with Onyx, he led accounting, SEC reporting, purchasing, tax, treasury, and risk management, among other responsibilities.

        Prior to Onyx, Mr. DeSouza held a senior role in assurance at Deloitte & Touche LLP. Mr. DeSouza began his career with more than a decade in assurance at Arthur Andersen LLP, where he managed client accounts, led audits and oversaw SEC filings. Mr. DeSouza earned a Bachelor’s of Business Administration degree from the University of Notre Dame.